11:01:05 EDT Sat 11 Jul 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
MedX Health Corp
Symbol MDX
Shares Issued 172,720,317
Close 2020-06-30 C$ 0.14
Recent Sedar Documents

MedX Health continues work on filing Q1 results July 13

2020-06-30 21:10 ET - News Release

Mr. Rob von der Porten reports

MEDX HEALTH CORP. PROVIDES UPDATE ON THE RELEASE OF ITS FIRST QUARTER 2020 INTERIM FINANCIAL STATEMENTS AND RELATED DISCLOSURES, AND RETIREMENT OF A DIRECTOR

MedX Health Corp. has provided an update on the filing of its interim financial statements and related disclosures for the first quarter of fiscal 2020, which was delayed owing to COVID-19-related issues. As previously announced in its press release dated May 27, 2020, the company anticipates that the interim disclosures will be filed by July 13, 2020.

In relation to the delay in filing of the interim disclosures, MedX relies on the provisions of Ontario Instrument 51-502 (Temporary Exemption from Certain Corporate Finance Requirements) and corresponding instruments in the other jurisdictions in which the company is a reporting issuer.

The company also announces that, as anticipated in its press release dated June 18, 2020, Scott Spearn has retired from the board of directors, effective June 30, 2020.

MedX confirms that there have been no material business developments other than as disclosed in its press releases and previous filings, and further confirms that management and other insiders of the company have been, since April 28, 2020, and continue to be subject to a trading blackout policy that reflects the principles in Section 9 of National Policy 11-207 (Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions), which will remain in effect until the interim disclosures have been filed.

About MedX Health Corp.

MedX, headquartered in Mississauga, Ont., is a leading medical device and software company focused on skin cancer with its DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also embedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485-certified facility. These products are Health Canada, Food and Drug Administration (United States), ARTG and CE cleared for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.